SQZ Biotechnologies

SQZ Biotechnologies EBIT Margin

The EBIT Margin (Operating Margin) of SQZ Biotechnologies (SQZB) as of Nov 3, 2026 is -498.25 %. In the previous year, EBIT Margin (Operating Margin) was -383.68 % — a change of 29.86% (lower).

EBIT Margin

-498.25 %

YoY

29.86%

Last updated:

EBIT Margin (Operating Margin) of SQZ Biotechnologies is 2023 -498.25 % . EBIT Margin (Operating Margin) of SQZ Biotechnologies was 2022 -383.68 % . It decreases by 29.86% lower compared to the previous year.

For SQZ Biotechnologies, the operating (EBIT) margin of -498.3% is down versus -170.4% a few years ago.

The SQZ Biotechnologies EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-161.05 USD
Jan 1, 2019
-170.40 USD
Jan 1, 2020
-243.16 USD
Jan 1, 2021
-253.78 USD
Jan 1, 2022
-383.68 USD
Jan 1, 2023
-498.25 USD
The SQZ Biotechnologies EBIT Margin history
YEAREBIT MarginYoY
-498.25 %+29.86%
-383.68 %+51.19%
-253.78 %+4.37%
-243.16 %+42.70%
-170.40 %+5.80%
-161.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SQZ Biotechnologies Stock analysis

What does SQZ Biotechnologies do? SQZ Biotechnologies Co. develops cell therapies for cancer, infectious diseases, and serious conditions through clinical-stage platforms. The company focuses on engineered antigen presentation to activate immune responses, with its SQZ Enhanced APC (eAPC) Platform generating tumor-specific CD8+ T cell activation for antitumor responses. The SQZ Activating Antigen Carrier (AAC) Platform uses red blood cells engineered with tumor antigens and adjuvants to induce in vivo antigen presentation, while the SQZ Tolerizing Antigen Carrier (TAC) Platform aims to establish immune tolerance via antigen-specific in vivo mechanisms. These platforms target oncology applications, with the eAPC and AAC candidates in clinical development. The company's revenue model relies on clinical development and partnerships for its cell therapy platforms. SQZ Biotechnologies Co. is a clinical-stage biotechnology firm, meaning it generates income through research and development funding, potential future licensing agreements, and partnerships with pharmaceutical companies. Its focus on oncology and immune activation positions it for collaboration with biopharma entities seeking to advance cell therapy technologies. The primary buyers of its technology are pharmaceutical companies interested in integrating these platforms into their therapeutic pipelines. SQZ Biotechnologies Co. targets the oncology segment for its cell therapy platforms, specifically focusing on tumor antigen-specific immune activation. The company's platforms are designed for patients with cancer, infectious diseases, and serious conditions, but its clinical-stage development is primarily directed at oncology applications. The SQZ eAPC and AAC platforms are in clinical development, with the company aiming to advance these candidates toward regulatory approval and commercialization. The TAC platform is also under development for immune tolerance applications, though it is not yet in clinical stages. SQZ Biotechnologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SQZ Biotechnologies stock

EBIT Margin (Operating Margin) of SQZ Biotechnologies is -498.25 % in 2023.

EBIT Margin (Operating Margin) of SQZ Biotechnologies changed from -383.68 % to -498.25 %, representing a 29.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) SQZ Biotechnologies since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s SQZ Biotechnologies with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — SQZ Biotechnologies

All Key Metrics — SQZ Biotechnologies